ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0725

Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis

Rennie Rhee1, Christine Yeung2, Darrin White3, Mary Gibson3, Jessica Nguyen4, Cristina Burroughs5, Jennifer Gordon6, Noam A. Cohen4, Jeffrey Morris4 and Peter Merkel1, 1University of Pennsylvania, Philadelphia, PA, 2Vasculitis Patient-Powered Research Network, Philadelphia, PA, 32. Patient Research Partner, Vasculitis Patient-Powered Research Network, Philadelphia, 4University of Pennsylvania, Philadelphia, 5University of South Florida, Tampa, FL, 6Vasculitis Foundation, Kansas City, MO

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Disease Activity, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found that a patient questionnaire called the Sino-Nasal Outcome Test-22 (SNOT-22), a validated patient-reported outcome measure in chronic rhinosinusitis, is associated with future relapse even in patients without a prior history of sinonasal disease. A detailed understanding of sinonasal symptoms is still lacking in AAV. The aim of this analysis was to evaluate sinonasal symptom profiles associated with disease activity in patients with AAV.

Methods: Patients with a self-reported diagnosis of AAV were recruited between January and March 2025 through an international research network (Vasculitis Patient-Powered Research Network). Participants rated 26 sinonasal symptoms on a scale from 0 (no problem) to 5 (problem as bad as it can be); the 26 symptoms included the original 22 items from the SNOT-22 plus four additional items related to vasculitis. The 4 vasculitis-specific items were selected based on patient and investigator input and included: nasal crusting, blood-tinged nasal discharge/crusts, nose bleeds, and nasal pain. Total and subdomain scores of the SNOT-22 were compared using linear regression. Sinonasal symptoms associated with active vasculitis versus remission were determined using LASSO-penalized logistic regression. The penalty term (λ) was chosen by 10-fold cross-validation; variables with nonzero coefficients were carried forward into a post-LASSO unpenalized model to estimate odds ratios (ORs) and 95% confidence intervals (CIs).

Results: A total of 663 participants with AAV from 24 countries were included: 130 with active disease, 423 in remission, and 110 who had unknown disease status. Median age at enrollment was 63 years, median disease duration was 8 years, 91% had positive ANCA in the past, and 88% had a prior history of sinonasal disease related to vasculitis. Total and subdomain SNOT-22+ scores were all significantly higher in active vasculitis vs remission group (Figure 1) and remained significant even after adjusting for age, sex, and disease duration. Both groups had higher scores compared to historical healthy control cohorts (mean score 9). Responses to 25 of 26 items were significantly higher in the active vs remission group (Figure 2). LASSO-based variable selection identified 12 items associated with disease activity (Figure 3).

Conclusion: Active AAV is associated with greater sinonasal symptom burden compared to quiescent disease although patients in remission continue to experience higher levels of symptoms compared to healthy patients. More severe nasal pain, more sadness, and less severe sneezing had the strongest association with active disease. A detailed understanding of the sinonasal symptom profile associated with active disease may improve clinical monitoring of disease activity in AAV.

Supporting image 1Figure 1. Comparison of Sino-Nasal Outcome Test scores by disease activity in patients with ANCA-associated vasculitis. Mean (SD) of total and subdomain scores from the SNOT-22 plus additional vasculitis-specific questions. Compared to patients with AAV in remission, patients with active disease had a greater burden of sinonasal symptoms and poorer quality of life across all domains (all P < 0.01).

Supporting image 2Figure 2. Mean response to individual items in the Sino-Nasal Outcome Test by disease activity in ANCA-associated vasculitis. Heatmap depicts the mean response to each item by group (active vs remission). Responses to all items except “wake up tired” were significantly higher in the active vs remission group (all P < 0.05). Items with asterisk and red font were retained in the final model after variable selection.

Supporting image 3Figure 3. Odds ratio with 95% CI for association of sinonasal items with active disease in ANCA-associated vasculitis. Figure displays variables selected in post-LASSO logistic regression model. Nasal pain, feeling sad, sneezing, and lack of good night’s sleep were among the items associated with disease activity in AAV in the multivariable model.


Disclosures: R. Rhee: None; C. Yeung: None; D. White: None; M. Gibson: None; J. Nguyen: None; C. Burroughs: None; J. Gordon: None; N. Cohen: None; J. Morris: None; P. Merkel: AbbVie, 2, 5, Alpine, 2, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb (BMS), 2, 5, CSL Behring, 2, Eicos, 5, Electra, 5, GlaxoSmithKlein (GSK), 2, 5, iCell, 2, Interius, 2, Kinevant, 2, Kyverna, 2, 11, Lifordi, 11, Metagenomia, 2, Neutrolis, 2, 5, 11, Novartis, 2, NS Pharma, 2, Otsuka, 2, Q32, 2, 11, Quell, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, 11, Takeda, 2, 5, UpToDate, 9, Vistera, 2.

To cite this abstract in AMA style:

Rhee R, Yeung C, White D, Gibson M, Nguyen J, Burroughs C, Gordon J, Cohen N, Morris J, Merkel P. Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/sinonasal-symptom-profiles-associated-with-disease-activity-in-an-international-cohort-of-patients-with-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sinonasal-symptom-profiles-associated-with-disease-activity-in-an-international-cohort-of-patients-with-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology